title: Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
abstract: Myeloid-derived suppressor cells (MDSC) are believed to play a role in immune suppression and subsequent failure of T cells to mount an efficient anti-tumor response, by employing both direct T-cell inhibition as well as induction of regulatory T cells (Tregs). Investigating the frequency and function of immune suppressive cell subsets in the peripheral blood of 41 patients with prostate cancer (PC) and 36 healthy donors (HD) showed a significant increase in circulating CD14(+) HLA-DR(low/neg) monocytic MDSC (M-MDSC) and Tregs in patients with PC compared to HD. Furthermore, M-MDSC frequencies correlated positively with Treg levels. In vitro proliferation assay with autologous T cells confirmed M-MDSC-mediated T-cell suppression, and intracellular staining of immune suppressive enzyme iNOS revealed a higher expression in M-MDSC from patients with PC. Increased frequencies of M-MDSC correlated with known negative prognostic markers in patients with PC including elevated levels of lactate dehydrogenase and prostate-specific antigen. Accordingly, high levels of M-MDSC were associated with a shorter median overall survival. Our data strongly suggest that M-MDSC, possibly along with Tregs, play a role in establishing an immune suppressive environment in patients with PC. Moreover, correlation of M-MDSC frequency with known prognostic markers and the observed impact on OS could reflect a possible role in tumor progression. Further insight into the generation and function of MDSC and their interplay with Tregs and other cell types may suggest ways to tackle their induction and/or function to improve immunological tumor control.
authors.affiliation: Department of Hematology, Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev, Herlev Ringvej 75, 2730, Herlev, Denmark.
authors.forename: Manja
authors.initials: M
authors.lastname: Idorn
authors.forename: Tania
authors.initials: T
authors.lastname: Køllgaard
authors.forename: Per
authors.initials: P
authors.lastname: Kongsted
authors.forename: Lisa
authors.initials: L
authors.lastname: Sengeløv
authors.forename: Per
authors.initials: P
authors.lastname: Thor Straten
mesh_terms: D000368:Aged; D049109:Cell Proliferation; D002469:Cell Separation; D018450:Disease Progression; D005434:Flow Cytometry; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D008297:Male; D022423:Myeloid Cells / Q000166:cytology* / Q000276:immunology; D009362:Neoplasm Metastasis; D011379:Prognosis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000276:immunology / Q000473:pathology*; D050378:T-Lymphocytes, Regulatory / Q000166:cytology* / Q000276:immunology
references.citation: Int J Cancer. 2009 Sep 15;125(6):1372-9
references.pmid: 19533748
references.citation: Blood. 2011 Aug 25;118(8):2170-3
references.pmid: 21708889
references.citation: Cancer Immunol Immunother. 2012 Apr;61(4):453-68
references.pmid: 22331081
references.citation: J Exp Med. 2005 Apr 18;201(8):1257-68
references.pmid: 15824085
references.citation: J Immunol. 1998 Nov 15;161(10):5313-20
references.pmid: 9820504
references.citation: World J Clin Oncol. 2011 Dec 10;2(12):384-96
references.pmid: 22171281
references.citation: Gastroenterology. 2008 Jul;135(1):234-43
references.pmid: 18485901
references.citation: Cancer Res. 2010 Jun 1;70(11):4335-45
references.pmid: 20484028
references.citation: J Leukoc Biol. 2013 Apr;93(4):633-7
references.pmid: 23341539
references.citation: J Cell Physiol. 2010 Oct;225(1):196-205
references.pmid: 20648630
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3089-94
references.pmid: 16809734
references.citation: Nat Med. 2012 Aug;18(8):1254-61
references.pmid: 22842478
references.citation: Cancer Immunol Immunother. 2012 Feb;61(2):255-263
references.pmid: 22120756
references.citation: Clin Exp Immunol. 2005 Jun;140(3):540-6
references.pmid: 15932517
references.citation: J Clin Oncol. 2014 Mar 1;32(7):671-7
references.pmid: 24449231
references.citation: Prostate. 2010 Mar 1;70(4):443-55
references.pmid: 19902470
references.citation: Cancer Res. 2013 Apr 15;73(8):2435-44
references.pmid: 23423978
references.citation: Blood. 2011 Jun 16;117(24):6532-41
references.pmid: 21493801
references.citation: J Clin Oncol. 2010 Jan 1;28(1):126-31
references.pmid: 19917860
references.citation: Clin Cancer Res. 2014 Mar 15;20(6):1601-9
references.pmid: 24323899
references.citation: Nat Rev Immunol. 2005 Aug;5(8):641-54
references.pmid: 16056256
references.citation: J Mol Med (Berl). 2012 Nov;90(11):1343-55
references.pmid: 22660275
references.citation: J Immunol Methods. 2012 Jul 31;381(1-2):14-22
references.pmid: 22522114
references.citation: Neuro Oncol. 2010 Jul;12(7):631-44
references.pmid: 20179016
references.citation: Blood. 2006 Aug 1;108(3):804-11
references.pmid: 16861339
references.citation: Nat Rev Immunol. 2009 Mar;9(3):162-74
references.pmid: 19197294
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1099-105
references.pmid: 20100959
references.citation: Adv Cancer Res. 2010;107:57-117
references.pmid: 20399961
references.citation: Clin Cancer Res. 2009 Mar 15;15(6):2148-57
references.pmid: 19276286
references.citation: Cancer Immunol Immunother. 2009 Jan;58(1):49-59
references.pmid: 18446337
references.citation: J Clin Oncol. 2007 Jun 20;25(18):2546-53
references.pmid: 17577033
references.citation: J Immunol. 2017 Feb 1;198(3):981-985
references.pmid: 28115586
references.citation: J Int Med Res. 2011;39(4):1381-91
references.pmid: 21986138
references.citation: J Biol Chem. 2002 Jun 14;277(24):21123-9
references.pmid: 11950832
references.citation: Br J Cancer. 2002 Jan 21;86(2):168-78
references.pmid: 11870501
references.citation: Cancer Immunol Immunother. 2013 Aug;62(8):1421-30
references.pmid: 23764929
references.citation: Urology. 2010 Nov;76(5):1072-6
references.pmid: 20846711
references.citation: J Immunol Methods. 2010 Jul 31;359(1-2):28-36
references.pmid: 20641145
references.citation: Int J Cancer. 2010 Aug 15;127(4):759-67
references.pmid: 20518016
references.citation: Blood. 2009 Jan 22;113(4):827-36
references.pmid: 18941119
references.citation: J Exp Med. 2006 Jul 10;203(7):1701-11
references.pmid: 16818678
references.citation: Clin Immunol. 2012 Sep;144(3):250-68
references.pmid: 22858650
references.citation: Cancer Immunol Immunother. 2004 Oct;53(10):865-78
references.pmid: 15118842
references.citation: J Immunol. 2013 Apr 1;190(7):3815-23
references.pmid: 23460744
references.citation: Int J Urol. 2013 Oct;20(10):971-8
references.pmid: 23421558